A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy

A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy

<i>Background and Objectives</i>: Bone metastases in patients can cause significant quality-of-life declines due to skeletal-related events (SREs). SRE is defined as the occurrence of radiotherapy for bone pain, pathologic fracture, bone surgery, spinal cord compression, or hypercalcemia...

Full description

Saved in:
Bibliographic Details
Main Authors: İrem Öner, Hicran Anık, Bediz Kurt İnci, Pınar Kubilay Tolunay, Öztürk Ateş, Ülkü Yalçıntaş Arslan, Cengiz Karaçin
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Medicina
Subjects:
cdk4/6 inhibitor
ribociclib
palbociclib
denosumab
RANKL inhibitor
zoledronic acid
Online Access:https://www.mdpi.com/1648-9144/61/2/360
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items